Cell Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Cell Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The cell therapy market is expected to witness a CAGR of 6.8% over the forecast period.

The impact of the COVID-19 pandemic on the cell therapy market is expected to be significant as most of the companies have been focusing on the development of cell-based therapies for COVID-19 treatment. For instance, in April 2020, Calidi Biotherapeutics Inc. revealed that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells Inc. (PSC), received FDA approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. The impact of COVID-19 is also expected to show a positive impact on the studied market as most of the pharmaceutical, biotechnology, and research institutes have been focusing on the development of cell therapy-based treatment against COVID-19. For instance, in November 2020, Novartis obtained the license for the Mesoblast’s cell therapy remestemcel-L for the treatment of COVID-19. Thus, owing to the growing research activities pertaining to the development of cell therapies in treating SARS-CoV2 infection, the studied market is expected to be impacted during the COVID-19 pandemic era.

The cell therapy market is anticipated to witness healthy growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.

Chronic diseases and conditions are on the rise worldwide. According to the Global Alliance for Chronic Diseases (GACD) 2018, 1 in 10 individuals was predicted to have type 2 diabetes by 2035 worldwide, and diabetes is predicted to be the 7th leading cause of death by 2030. According to Globocan 2020, the new cancer cases diagnosed accounted for 19,292,789 in 2020 worldwide, with 9,958,133 deaths due to cancers globally. Among all cancers, breast cancer accounted for 2,261, 419 new cancer cases, followed by lung (2,206,771), prostate (1,414,259), and colon (1,148,515) in 2020. Additionally, as per the International Diabetes Federation Diabetes Altas Ninth Edition 2019, nearly 463 million population globally were living with diabetes worldwide, and the number is expected to reach 700 million by 2045.

Therefore, the increasing prevalence of chronic conditions, government assistance, and numerous companies investing heavily in stem cell therapy research and development are predicted to help to stimulate industry growth. The proven effectiveness of cell therapy products, coupled with the increasingly favorable guidelines on cell therapy research and manufacturing, is likely to positively impact the studied market over the forecast period.

Key Market TrendsThe Allogeneic Therapies Segment is Expected to Account for the Largest Share in the Cell Therapy Market

Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore, the increasing inclination of physicians towards therapeutic use of allogeneic therapies coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas are some of the major factors driving the growth. Allogenic cells have benefits as they produce their own immune stem cells that kill the cancer cells that remain even after high-dose treatment with cytotoxic drugs. This response is called a graft-versus-cancer effect, and this is used in the prevention or treatment of cancer relapse. The aforementioned factors are expected to drive the market over the forecast period.

Moreover, cancer recurrence is one of the foremost concerns of patients and their caregivers. Fear of recurrence can negatively affect the quality of life, and as per the “cancer recurrence statistics” published in 2018, approximately 7% of patients develop severe and disabling fear that includes constant intrusive thoughts and misinterpretation of mild and unrelated symptoms. These recurrences are usually observed in children and patients suffering from breast and oropharyngeal cancer. Allogenic transplantation is recommended for patients with a high risk of relapse after successive courses of induction chemotherapy. Thus, an increase in the incidence of cancer relapse has provided growth avenues to the demand for allogeneic therapies. Furthermore, the rising number of clinical trials required to gain regulatory approval for new medications to advance patient care is expected to boost the segment growth. For instance, ALLO-501, ALLO-501A, ALLO-715, UCART19, and UCART19 by Allogene provide growth opportunities to the segmental growth.

Thus, owing to the rising number of research on allogenic therapy for cancer and associated benefits, the studied segment is anticipated to register steady growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is estimated to retain the largest share of the cell therapy market due to the presence of a strong regulatory framework to promote cellular therapy development, the existence of industry key players, and the presence of leading universities that supports the research activities in the United States. Factors attributing to the high growth of the studied market in the region include the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.

There is a tremendous amount of funding in the United States available to increase R&D activities in the field of cancer. As per the data published by the National Cancer Institute (NCI), in 2019, the Department of Defense and Labor, the Department of Health and Human Services, and the Education Appropriations Act allotted USD 5.74 billion to the NCI, which indicated a USD 79 million increase over FY 2018. As cell therapies have huge potential in treating cancer, the availability of funding is expected to further help in overall market growth. In July 2020, the US FDA approved Tecartus (brexucabtagene autoleucel), cell-based gene therapy for the treatment of mantle cell lymphoma (MCL). In July 2020, FDA also approved Talaris Therapeutics Inc., an investigational new drug application for the evaluation of Talaris’ novel cell therapy FCR001 in the treatment of diffuse systemic sclerosis (SSC). Moreover, as per the Regulatory Affairs Professionals Society, in 2019, the US FDA granted 34 designations associated with regenerative medicine advanced therapy, wherein 68 out of 100 were cell therapy products. Thus, the rising adoption of regenerative medicines and related clinical studies in the region is anticipated to propel market growth over the forecast period.

Competitive Landscape

The cell therapy market is moderately competitive, with the presence of a considerable number of companies. The major companies of the studied market are Pharmicell Co. Ltd, Corestem Inc., Chiesi Farmaceutici SpA, Tegoscience, Anterogen Co. Ltd, TiGenix (Takeda Pharmaceuticals), Stempeutics Research Pvt Ltd, Nipro Corporation, and Medipost Co. Ltd. These companies are evolving through various strategies such as investment in research and development, acquisitions, partnerships, and collaborations to secure the market position. For instance, in January 2020, Allogene Therapeutics Inc. and SpringWorks Therapeutics Inc. announced a clinical trial collaboration agreement for the evaluation of ALLO-715, along with Nirogacestat in Multiple Myeloma patients.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Companies Mentioned

Anterogen Co. Ltd
Tego Science
Chiesi Farmaceutici SpA
Corestem Inc.
Pharmicell Co. Ltd
Fibrocell Technologies Inc.
Nipro Corporation
MEDIPOST Co. Ltd
TiGenix (Takeda Pharmaceuticals)
Stempeutics Research Pvt Ltd
Gilead Sciences Inc. (Kite Pharma Inc.)
Allogene Therapeutics Inc.
Novartis AG
Vericel Corporation
Organogenesis Inc.

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.